Michael Olusegun Adeduro, NP
Nurse Practitioner · Bakersfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 4 years
- Graduated 2022
Offices
3 locations · County of Kern · Tarzana Treatment Centers Inc
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Michael Olusegun Adeduro’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$9,328
Medicare paid this office $9,328 for 30 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Psychiatric diagnostic evaluation with medical services | 21 | $5,219 | $111 |
| Return visit (30+ min) | 14 | $3,294 | $70 |
Who their Medicare patients are
30 Original Medicare patients in 2024. Average age 49 · Women 43% · Health risk score 1.33. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: Depression 47% · High blood pressure 43% · Diabetes 37%.
The office billed $32,142, Medicare allowed $12,896 and paid $9,328; for 104 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$245,599
Pharmacies billed $245,599 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 691) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
609 generic and 82 brand-name prescriptions · $245,599 in drug cost · 42 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Invega Sustenna | 75 | $215,202 | $2,869 |
| Clozapine | 46 | $5,282 | $115 |
| Aripiprazole | 31 | $1,602 | $52 |
| Olanzapine | 51 | $878 | $17 |
| Divalproex | 35 | $730 | $21 |
See all 19 drugs
| Invega Sustenna | 75 | $215,202 | $2,869 |
| Clozapine | 46 | $5,282 | $115 |
| Aripiprazole | 31 | $1,602 | $52 |
| Olanzapine | 51 | $878 | $17 |
| Divalproex | 35 | $730 | $21 |
| Quetiapine Fumarate Er | 16 | $658 | $41 |
| Oxcarbazepine | 13 | $649 | $50 |
| Dextroamphetamine-Amphetamine | 17 | $461 | $27 |
| Gabapentin | 52 | $394 | $8 |
| Trazodone | 24 | $279 | $12 |
| Benztropine Mesylate | 32 | $269 | $8 |
| Risperidone | 60 | $253 | $4 |
| Hydroxyzine Pamoate | 19 | $210 | $11 |
| Lithium Carbonate Er | 13 | $198 | $15 |
| Duloxetine | 21 | $196 | $9 |
| Mirtazapine | 26 | $157 | $6 |
| Quetiapine | 12 | $103 | $9 |
| Escitalopram | 13 | $32 | $2 |
| Amitriptyline | 12 | $31 | $3 |
Year by year
| 2024 | 691 | 76 | 0% (0) | 12% | $245,599 |
| 2023 | 116 | 31 | 0% (0) | 9% | $32,104 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Gabapentin | 12 | $150 | $12 |
Money from drug and device companies
$300 in 2025
| 2025 | 7 | 24 | None | $300 |
| 2024 | 7 | 18 | None | $480 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Pharmaceuticals | Invega Sustenna | $156 | 15 payments
|
| Otsuka America Pharmaceutical | Rexulti | $44 | 3 payments
|
| Neurocrine BioSciences | Ingrezza | $39 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $23 | 1 payment
|
| Lundbeck | Abilify Asimtufii | $16 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $15 | 1 payment
|
See all 24 published payments
| Janssen Biotech | Meals · 2025-12-04 | Invega Sustenna | $7 |
| Janssen Pharmaceuticals | Meals · 2025-11-06 | Invega Sustenna | $11 |
| Janssen Pharmaceuticals | Meals · 2025-10-02 | Invega Sustenna | $12 |
| Otsuka America Pharmaceutical | Meals · 2025-09-25 | Rexulti | $14 |
| Janssen Pharmaceuticals | Meals · 2025-09-04 | Invega Sustenna | $19 |
| Janssen Pharmaceuticals | Meals · 2025-08-14 | Invega Sustenna | $11 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-11 | Cobenfy | $15 |
| Janssen Pharmaceuticals | Meals · 2025-07-17 | Invega Sustenna | $11 |
| Neurocrine BioSciences | Meals · 2025-06-17 | Ingrezza | $19 |
| Teva Pharmaceuticals USA | Meals · 2025-06-12 | Austedo Xr | $23 |
| Janssen Pharmaceuticals | Meals · 2025-06-05 | Invega Sustenna | $11 |
| Otsuka America Pharmaceutical | Meals · 2025-05-29 | Abilify Asimtufii | $16 |
| Janssen Pharmaceuticals | Meals · 2025-05-01 | Invega Sustenna | $10 |
| Lundbeck | Meals · 2025-04-21 | Abilify Asimtufii | $16 |
| Janssen Pharmaceuticals | Meals · 2025-04-03 | Invega Sustenna | $10 |
| Janssen Pharmaceuticals | Meals · 2025-04-03 | Invega Sustenna | $1 |
| Janssen Pharmaceuticals | Meals · 2025-03-13 | Invega Sustenna | $11 |
| Janssen Pharmaceuticals | Meals · 2025-03-06 | None | $23 |
| Neurocrine BioSciences | Meals · 2025-02-16 | Ingrezza | $20 |
| Janssen Pharmaceuticals | Meals · 2025-02-06 | Invega Sustenna | $10 |
| Janssen Pharmaceuticals | Education · 2025-02-06 | None | $5 |
| Janssen Pharmaceuticals | Meals · 2025-02-06 | Invega Sustenna | $2 |
| Otsuka America Pharmaceutical | Meals · 2025-01-13 | Rexulti | $14 |
| Janssen Pharmaceuticals | Meals · 2025-01-06 | Invega Sustenna | $7 |
See earlier years (2024)
2024: $480
| Janssen Pharmaceuticals | Invega Sustenna | $327 | 10 payments
|
| Otsuka America Pharmaceutical | Abilify Asimtufii | $43 | 2 payments
|
| Lundbeck | Abilify Asimtufii | $35 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | None | $25 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo Xr | $19 | 1 payment
|
| Abbvie | Vraylar | $18 | 1 payment
|
| Alkermes | Aristada | $13 | 1 payment
|
Professional record
- NPI
- 1386352789
- Licence
- CA 95023296
- Group
- County of Kern · Tarzana Treatment Centers Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 4653 Vahan Ct, Lancaster, CA, 93536
- NPI first listed
- 2022-11-14
- NPI last updated
- 2022-11-14
- NPI record certified
- 2022-11-14
This is when the NPI record was last certified, not a medical board exam.